The journey of peptidomimetic ADP355 (vide supra) from a potential systemic cancer therapeutic to impending clinical trials as eye drops against dry eye disease (28) provides confidence that systematic research on adiponectin functions and potential adiponectin receptor response modifiers may lead to novel therapeutics. Here, ADIPOQ is linked to cancer.